Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by State Street Corp

State Street Corp boosted its stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 1.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 816,634 shares of the company’s stock after acquiring an additional 14,711 shares during the quarter. State Street Corp owned about 1.55% of Kodiak Sciences worth $2,131,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its holdings in shares of Kodiak Sciences by 14.1% in the second quarter. Acadian Asset Management LLC now owns 1,965,449 shares of the company’s stock valued at $4,614,000 after acquiring an additional 242,559 shares in the last quarter. Renaissance Technologies LLC lifted its position in Kodiak Sciences by 21.9% in the second quarter. Renaissance Technologies LLC now owns 708,800 shares of the company’s stock valued at $1,666,000 after purchasing an additional 127,400 shares during the period. GSA Capital Partners LLP purchased a new stake in Kodiak Sciences in the 3rd quarter valued at approximately $751,000. FMR LLC increased its position in Kodiak Sciences by 26.4% during the 3rd quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after purchasing an additional 41,987 shares during the period. Finally, Marshall Wace LLP raised its stake in shares of Kodiak Sciences by 41.6% during the 2nd quarter. Marshall Wace LLP now owns 166,425 shares of the company’s stock worth $391,000 after buying an additional 48,930 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Stock Performance

Shares of KOD stock opened at $9.95 on Thursday. The stock has a fifty day moving average price of $6.75 and a 200 day moving average price of $4.12. The stock has a market cap of $523.61 million, a PE ratio of -2.73 and a beta of 2.38. Kodiak Sciences Inc. has a 1 year low of $2.18 and a 1 year high of $11.60.

Analysts Set New Price Targets

KOD has been the topic of a number of analyst reports. HC Wainwright restated a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a research note on Friday, November 15th. Barclays boosted their target price on shares of Kodiak Sciences from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group upgraded shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Monday, December 9th.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.